Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

740 Y-P

🥰Excellent
Catalog No. TQ0003Cas No. 1236188-16-1
Alias PDGFR 740Y-P, 740YPDGFR

740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.

740 Y-P

740 Y-P

🥰Excellent
Purity: 99.87%
Catalog No. TQ0003Alias PDGFR 740Y-P, 740YPDGFRCas No. 1236188-16-1
740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.
Pack SizePriceAvailabilityQuantity
1 mg$89In Stock
2 mg$139In Stock
5 mg$265In Stock
10 mg$393In Stock
25 mg$658In Stock
50 mg$937In Stock
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Batch Information

Select Batch
Purity:99.87%
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85.
Targets&IC50
SGC - 996 Cell:9.32 μM, NOZ cells:9.91 μM
In vitro
METHODS: C2 muscle cells were treated with 740 Y-P (50 μg/mL) for 48 hours, and the cell cycle was observed and analyzed using an ultraviolet fluorescence microscope.
RESULTS: Mitosis in the 740 Y-P-specific stimulation medium was superior to EGF or FGF in stimulating the entry into the S phase. It showed that the percentage of S phase cells in C2 cells was 48.3%. [1]
METHODS: PC12 cells were treated with 740 YP (30 μM) for 24 hours, and the LC3-II/LC3-I levels were detected by western blot.
RESULTS: 740 YP significantly inhibited the LC3-II/LC3-I levels in PC12 cells induced by GO. [2]
In vivo
METHODS: To study the neuroprotective effect of 740 Y-P, 740 Y-P (10 mg/kg) was intraperitoneally injected into the rat model of Alzheimer's disease (AD) for 6 weeks.
RESULTS: 740 Y-P can reduce the ROS (reactive oxygen species) level in hippocampal tissue after treatment with Aβ(25-32), and increase the phosphorylation degree of AKT and PI3K. This indicates that 740 Y-P has a certain neuroprotective effect in vivo, which may be achieved by activating the PI3K/Akt signaling pathway. [3]
METHODS: To study the role of 740 Y-P in cardiac hypertrophy, 740 Y-P (10 mg/kg) was intraperitoneally injected into mice for 6 weeks.
RESULTS: 740 Y-P can significantly increase the ratio of heart weight to body weight (HW/BW) and the ratio of heart weight to tibial length (HW/TL), and increase the cross-sectional area of cardiomyocytes. Furthermore, 740 Y-P can also increase the expression of hypertrophy related genes such as ANP, BNP and β-MHC in cardiomyocytes, indicating that it can promote cardiac hypertrophy in vivo. [4]
METHODS: To study the analgesic effect of 740 Y-P, 740 Y-P (1, 5, 10, 20 µg/5 µL) was intrathecally injected into a mouse model of chronic constriction injury of the sciatic nerve (CCI).
RESULTS: At doses of 10 and 20 µg/5 µL, 740 Y-P can significantly alleviate tactile and thermal hypersensitivity caused by CCI. 740 Y-P showed significant analgesic effects within 1.5, 3 and 5 hours after injection, but the effect was no longer significant after 24 hours. [5]
SynonymsPDGFR 740Y-P, 740YPDGFR
Chemical Properties
Molecular Weight3270.7
FormulaC141H222N43O39PS3
Cas No.1236188-16-1
SmilesC([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6
Relative Density.1.51 g/cm3 (Predicted)
SequenceArg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Ser-Asp-Gly-Gly-{Tyr(PO2)}-Met-Asp-Met-Ser
Sequence ShortRQIKIWFQNRRMKWKKSDGG-{Tyr(PO2)}-MDMS
Storage & Solubility Information
Storagestore at low temperature,store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 50 mg/mL (15.29 mM), Sonication is recommended.
H2O: 5.5 mg/mL (1.68 mM), when pH is adjusted with HCl. Sonication is recommmended.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM0.3057 mL1.5287 mL3.0574 mL15.2872 mL
DMSO
1mg5mg10mg50mg
5 mM0.0611 mL0.3057 mL0.6115 mL3.0574 mL
10 mM0.0306 mL0.1529 mL0.3057 mL1.5287 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy 740 Y-P | purchase 740 Y-P | 740 Y-P cost | order 740 Y-P | 740 Y-P chemical structure | 740 Y-P in vivo | 740 Y-P in vitro | 740 Y-P formula | 740 Y-P molecular weight